



CDF: combinación a dosis fija.

\*Ahorro en este caso, hace referencia al gasto sanitario directo evitable<sup>5</sup>. <sup>1</sup>En comparación con la suma de medicamentos individuales<sup>6</sup>.

<sup>1</sup>. Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drugs. 2007;7(6):413-22. <sup>2</sup>. Rea F, Savaré L, Corrao G, et al. Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe. Adv Ther. 2021 Oct;38(10):5270-5285. <sup>3</sup>. Castellano JM, Sanz C, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol. 2014;64(6):613-21. <sup>4</sup>. Belsey, J. D. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ 2012; 15: 897-905. <sup>5</sup>. Farmaindustria. Plan de adherencia al tratamiento: Uso responsable del medicamento. Disponible en: <https://www.farmaindustria.es/adherencia/> (Último acceso: marzo 2022). <sup>6</sup>. Drexel H, Coats AJS, Spoletini I, et al. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):115-121.